Apogee Therapeutics APGE 深 沪
等待开盘 10-24 09:30:00 美东时间
53.235
-0.245
-0.46%
华盛通- 最 高57.34
- 今 开53.77
- 成交量 19.92万股
- 最 低 51.80
- 昨 收 53.48
- 总市值 31.73亿
- 52周最高 63.50
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 26.20
- 委 比 91.67%
- 总股本 5959.64万
- 历史最高 72.29
- 量 比 0.35
- 振 幅 10.36%
- 历史最低 14.19
- 每 手 1
- 风险率 6.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105
Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Outperform rating and announces Price Target of $105.
10-21 20:42
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
Apogee Therapeutics完成8,048,782股普通股的公开募股，每股41美元，总募股额约3.45亿美元。此外，提供365,853股预资助认股权证，总价值约1480万美元，总募资约3.45亿美元。公司专注于炎症和免疫学市场的生物制剂开发，旨在最佳治疗如湿疹、哮喘等疾病。
10-10 20:01
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
BTIG Reiterates Buy on Apogee Therapeutics, Maintains $115 Price Target
BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $115 price target.
10-09 22:53
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
10-09 17:58
Biggest stock movers Thursday: AZZ, RELL, and more
Stock futures were largely unchanged in premarket trading on Thursday, following a strong tech rally that pushed the Nasdaq to a new record high in the previous session. Here are some of Thursday's bi...
10-09 17:00
Apogee Therapeutics prices $300M public offering
Apogee Therapeutics (NASDAQ:APGE) priced its public offering at $41 per share, raising ~$300M in gross proceeds. The offering includes 6.95M common shares and 365,853 pre-funded warrants priced at $41...
10-09 14:18
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 32.1% to...
10-09 05:06
